Strong First Quarter Performance#
Stifel has reaffirmed a Buy rating for Edwards Lifesciences (NYSE: EW) following the company’s impressive first-quarter earnings report for fiscal 2026. The medical device company reported revenue of $1.65 billion, exceeding the expected $1.6 billion. Additionally, its adjusted earnings per share (EPS) reached $0.78, surpassing the forecast of $0.73.
Growth in Key Products#
The company’s transcatheter aortic valve replacement (TAVR) product has shown remarkable growth, achieving double-digit increases for the third consecutive quarter. This reflects strong investor confidence, as indicated by the company’s price-to-earnings (P/E) ratio of 44, which is a measure of how much investors are willing to pay for each dollar of earnings. Furthermore, Edwards Lifesciences’ PASCAL minimally invasive mitral-valve-repair product gained market share during this quarter.
Adjusted Financial Guidance#
Following these positive results, Edwards Lifesciences has raised its financial guidance for 2026. However, management has cautioned that the second half of the year may present tougher year-over-year comparisons, potentially leading to slower revenue growth during that period. The company is optimistic about future growth, citing extensive data supporting its TAVR product and an upcoming update from the Centers for Medicare & Medicaid Services (CMS) as potential catalysts.
Analyst Reactions#
In response to the strong earnings, various analysts have adjusted their price targets for Edwards Lifesciences. BTIG raised its target to $100 from $98, while Canaccord lowered its target to $85 from $87, maintaining a Hold rating. Truist Securities increased its target to $90 from $89, and Barclays raised its target to $110 from $104, reflecting confidence in the company’s continued financial strength and growth potential.